Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

Phase 2 Completed 82 enrolled Spanish Lymphoma Cooperative Group

NaSingle-groupOpen-labelTreatment

The purpose of this study is to determine efficacy of rituximab, gemcitabine, oxaliplatin and dexametasone (R-GemOx) chemotherapy schedule.

Evaluation	Drug	Modality	Dose	Route
Subject	Dexamethasone	Small molecule	20 mg	Oral
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	Oxaliplatin	Small molecule	100 mg/m2	Intravenous
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous